Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 8/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195734 | 0.98 | CA14 (0.47) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL17299743 | 0.92 | TDP1 (0.44) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL13055403 | 0.92 | CA14 (0.54) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL13055414 | 0.90 | CA14 (0.53) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL13055399 | 0.90 | CA14 (0.53) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL13055411 | 0.90 | CA14 (0.53) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL18543816 | 0.90 | CA14 (0.43) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL10181287 | 0.88 | CA14 (0.53) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL2909636 | 0.88 | CA14 (0.44) | CA14TDP1MAOAMAOBMEN1 | |
| SCHEMBL18342083 | 0.88 | MEN1 (0.46) | CA14TDP1MAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| CN-118414171-A | Oligosaccharide complexes and uses | 生物技术公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-2393495-A1 | CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2011-12-14 | — | — | EP | disclosed |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20100285570-A1 | FLUORIDE PROCESSING METHOD | JACKSON ALEXANDER | 2010-11-11 | — | — | US | disclosed |
| WO-2010089752-A1 | CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2010-08-12 | — | — | WO | disclosed |
| US-20100178242-A1 | LABELLING METHODS | GE HEALTHCARE LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100178242-A1 | LABELLING METHODS | GE HEALTHCARE LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| WO-2009083530-A2 | FLUORIDE PROCESSING METHOD | GE HEALTHCARE LIMITED (GB) | 2009-07-09 | — | — | WO | disclosed |
| US-20040005274-A1 | Targeting multimeric imaging agents through multilocus binding | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6652835-B1 | Improved relaxivity properties upon binding | EPIX MEDICAL, INC. | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | CA14 3997/4885TDP1 3724/4885MAOA 4788/4885 |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | CA14 1352/4885TDP1 2485/4885MAOA 4709/4885 |
| US-20100285570-A1 | FLUORIDE PROCESSING METHOD | SLCO1B1, CTSF, MEN1 | CA14 21/4885TDP1 1799/4885MAOA 1661/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | CA14 841/4885TDP1 4398/4885MAOA 4757/4885 |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | CA14 3997/4885TDP1 3724/4885MAOA 4788/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | CA14 3267/4885TDP1 4468/4885MAOA 4861/4885 |
| US-20100178242-A1 | LABELLING METHODS | FURIN, FGF23, FGF2 | CA14 63/4885TDP1 3059/4885MAOA 2500/4885 |
| US-20040005274-A1 | Targeting multimeric imaging agents through multilocus binding | ILK, PBRM1, FABP1 | CA14 1562/4885TDP1 3568/4885MAOA 3453/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | CA14 419/4885TDP1 1188/4885MAOA 3019/4885 |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | CA14 1431/4885TDP1 3844/4885MAOA 1898/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | CA14 3997/4885TDP1 3724/4885MAOA 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.